Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing...
At the recent launch of PsyPal, the first EU-funded clinical research project focused on psychedelic-assisted mental health treatments, MEPs were informed...
At the recent launch of PsyPal, the first EU-funded clinical research project focused on psychedelic-assisted mental health treatments, MEPs were informed...
Governor Eric Holcomb of Indiana has recently enacted a law that earmarks funds for clinical trials to explore the therapeutic effects of psilocybin. This...
Governor Eric Holcomb of Indiana has recently enacted a law that earmarks funds for clinical trials to explore the therapeutic effects of psilocybin. This...
Diabetes, a chronic condition marked by elevated blood sugar levels, is projected to affect over 700 million people globally by 2045. As the prevalence...
Diabetes, a chronic condition marked by elevated blood sugar levels, is projected to affect over 700 million people globally by 2045. As the prevalence...
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing...
SARASOTA, FL, April 10, 2024 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical...
On April 16th, moderator David Rahn of Psy-Ins will sit with ketamine providers that have built or are currently building their ketamine companies. During...